Aging of established antiviral T cell memory fosters a series of progressive adaptations that paradoxically improve rather than compromise protective CD8 + T cell immunity. We now provide evidence that this gradual evolution, the pace of which is contingent on the precise context of the primary response, also impinges on the molecular mechanisms that regulate CD8 + memory T cell (CD8 + T M ) homeostasis. Over time, CD8 + T M become more resistant to apoptosis and acquire enhanced cytokine responsiveness without adjusting their homeostatic proliferation rates; concurrent metabolic adaptations promote increased CD8 + T M quiescence and fitness but also impart the re-acquisition of a partial effector-like metabolic profile; and a gradual redistribution of aging CD8 + T M from blood and nonlymphoid tissues to lymphatic organs results in CD8 + T M accumulations in bone marrow, splenic white pulp and particularly lymph nodes. Altogether, these data demonstrate how temporal alterations of fundamental homeostatic determinants converge to render aged CD8 + T M poised for greater recall responses.
INTRODUCTION
The long-term preservation of antiviral T cell memory is a highly dynamic process that promotes the progressive molecular, phenotypic and functional remodeling of its principal constituents, the populations of specific CD8 + memory T cells (CD8 + T M ) distributed throughout and often trafficking between various anatomic compartments. We recently demonstrated that this process can culminate, paradoxically, in the acquisition of naïve-like T cell traits, enhanced recall potential and greater protective capacities of aged CD8 + T M [1] . The notion that aging can improve CD8 + T cell memory [1] [2] [3] [4] [5] stands in apparent contrast to much of the literature documenting numerous and often deleterious consequences of T cell aging [6] [7] [8] [9] . A more focused review [10] , however, indicates that eventual "immunosenescence" is not necessarily a fate shared by all T cell subsets and CD8 + T M generated earlier in life to an acute, non-persisting pathogen challenges can be maintained over time without accruing obvious functional defects [9, 11, 12] . In fact, a coexistence of age-associated alterations that either impair or improve CD8 + T cell immunity is illustrated in aged mice that exhibit a diminished capacity for generation of primary (I o ) antiviral CD8 + effector T cell (CD8 + T E ) responses yet readily support the greater secondary (II o ) expansion of old as compared to young CD8 + T M specific for the same viral determinants [1] .
To elucidate the foundations and consequences of successful CD8 + T M aging in greater detail, we previously generated a set of integrated data sets that collectively trace the evolving molecular, phenotypic and functional properties of aging virus-specific CD8 + T M [1] . We further organized the patterns of gradual CD8 + T M remodeling in a conceptual framework designated the "rebound model" of progressive CD8 + T M "dedifferentiation" that postulates an inverse relationship between the extent of I o CD8 + T E differentiation and the pace with which aging CD8 + T M populations, over a period of ~2 years, acquire a broad spectrum of distinctive and increasingly homogenous traits. Specifically, aging of CD8 + T M populations modulates the expression of at least ~80 cell surface receptors/ligands, produces a more diversified functional repertoire, and eventually endows old CD8 + T M in a T cell-intrinsic fashion with an improved capacity for the generation of protective II o responses [1] . In the present report, we have delineated the impact of aging on the cardinal components of CD8 + T M homeostasis (survival, homeostatic proliferation, metabolism, tissue residence/trafficking) and our findings demonstrate that the cumulative homeostatic adaptations converge to establish a spatio-functional foundation for improved recall responses of aged CD8 + T M .
RESULTS AND DISCUSSION

Temporal regulation of survival-& apoptosis-related gene and protein expression by aging CD8 + T M .
Challenge of mice with the natural murine pathogen lymphocytic choriomeningitis virus (LCMV) induces a potent antiviral CD8 + T E response that rapidly controls the infection and permits the subsequent development of specific CD8 + T M that are maintained for life in the absence of residual viral antigens [13, 14] . In B6 mice, the principal LCMV-specific CD8 + T cell populations target the nucleo-and glycoprotein determinants NP 396-404 and GP [33] [34] [35] [36] [37] [38] [39] [40] [41] ; in addition, naïve TCRtg p14 cells specific for LCMV-GP [33] [34] [35] [36] [37] [38] [39] [40] [41] and transferred into congenic B6 mice can be used to construct "p14 chimeras" for facilitated interrogation of a clonotypic CD8 + T M population (p14 T M ). A combination of p14 chimera and B6 systems provided the experimental foundation for our comprehensive delineation of aging antiviral CD8 + T M properties [1] , and drawing on these resources, we have now revisited the foundations of long-term CD8 + T M survival [15] by conducting modified gene set enrichment analyses (GSEAs) that specifically leverage the temporal aspect of our p14 T M data sets (see Methods). Here, of 132 gene sets comprising 10,945 genes and exhibiting age-associated modulations, ~20% (26/132) were enriched and ~80%
(106/132) were depleted in old p14 T M , the latter group including the KEGG apoptosis pathway (Fig.1A ). Within this module, 14 genes belonged to the Bcl-2, BIRC (baculoviral IAP [inhibitors of apoptosis proteins] repeatcontaining) or caspase gene families and their combined temporal regulation pointed towards reduced apoptosis susceptibility of aged p14 T M (Fig.1A) .
Members of the Bcl-2 family have long been implicated in lymphocyte survival and death, and the balanced expression of anti-apoptotic Bcl-2 and pro-apoptotic BIM controls survival of naïve and, to a somewhat lesser extent, memory phenotype CD8 + T cells (CD8 + T N and CD8 + T MP , respectively) [16] . Our interrogation of individual Bcl-2 family members revealed predominantly stable expression by aging p14 T M with two notable exceptions, the modestly rising levels of Bcl2 and Bcl2l11 (Fig.S1A-C) . Importantly, the transcriptional changes were accompanied by a substantial increase of Bcl-2 protein content in aging CD8 + T M and a slight, though significant, enhancement of BIM such that the resulting Bcl-2:BIM expression ratio steadily increased over time ( Fig.1B/C) . Given a progressive enrichment for the CD62L hi phenotype among aging antiviral CD8 + T M [1, 17] , our findings are also in agreement with the reported elevation of both Bcl-2 and BIM in antiviral CD8 + T CM as compared to T EM populations [18] . We emphasize, however, that these expression differences themselves are subject to an extended temporal modulation since the continuous rise of the Bcl-2:BIM ratios occurred in aging CD8 + T CM and T EM subsets alike (Fig.1C ). We also note the persistence of relatively stable Bcl-x L levels (Fig.1D) ; a gradual increase of several BIRC family genes that may contribute to an enhanced survival advantage for aged CD8 + T M [19, 20] (Fig.S1D) ; and the pronounced decline of Casp3 mRNA without evidence for caspase-3 activation [21] throughout long-term T cell memory ( Figs.1D & S1E) . Altogether, the kinetics of gene and protein expression therefore indicate that aging CD8 + T M may be endowed with increasing overall fitness.
Enhanced apoptosis resistance of aging CD8 + T M .
When assessed directly ex vivo, the viability of CD8 + T M was not affected by age ( Fig.2A ), but an in vitro culture in the absence of added growth/survival factors ("withdrawal apoptosis") documented a gradual decline of CD8 + T M death as a function of age ( Fig.2B ). Increased apoptosis resistance has been associated with aging and cellular senescence [22] but the CD8 + T M under investigation here lacked phenotypic and functional features of incapacitation [1] , including the hallmark of murine T cell senescence, increased P-glycoprotein activity [23] .
Nonetheless, a distinct survival advantage of "non-senescent" old CD8 + T MP was previously observed under conditions of "withdrawal apoptosis" and attributed, despite an exacerbated decline of mitochondrial membrane potentials (ΔΨm), to reduced production of reactive oxygen species (ROS), elevated intracellular thiol levels (largely representing the abundance of reduced glutathione/GSH), and increased expression of phase II antioxidant enzymes that combine to protect aged CD8 + T MP against oxidative stress, mitochondrial dysfunction and death [24, 25] . In our model system, aging virus-specific CD8 + T M also exhibited a modest decline of ex vivo ROS production ( Fig.2C ) and a more striking loss of ΔΨm after in vitro culture ( Fig.2D ). Yet despite an enrichment of genes within the GSH metabolism pathway ( Fig.2E ) that may collectively provide a metabolic advantage [26] for recall responses, we observed only a marginal rise of intracellular thiol levels in aging CD8 + T M (Fig.2F ), and regardless of a 1.9-fold increase of Nfe2l2 mRNA [1] (the major TF in control of phase II enzyme regulation), no evidence for elevated induction of the respective genes could be obtained (not shown).
Instead, we found a pronounced augmentation of cell surface thiol levels by aging CD8 + T M that was likely the result of changing microenvironments in older mice as demonstrated by their significantly increased serum thiol levels ( Fig.2G ); this conclusion is also consistent with the notion that the immediate microenvironment rather than intracellular GSH levels preferentially determines the redox status of cell surface molecules [27] .
Life & death of aging CD8 + T M : improved survival through increased Bcl-2:BIM expression ratios.
Collectively, the above observations suggest that T cell-intrinsic mechanisms, in particular the rising Bcl-2:BIM expression ratio, may confer a survival advantage to aging CD8 + T M . To directly evaluate this possibility we employed a co-culture system to monitor survival of congenic old and young CD8 + T M in the same in vitro environment. Addition of the Bcl-2 inhibitor ABT-737 [28] to cultures precipitated CD8 + T cell death in a dosedependent fashion and, at a saturating concentration of 150nM, reduced total CD8 + T cell survival to ~10% 
In the context of an acute response, both I o and II o CD8 + T E downregulate Bcl-2 expression [29] , and control of CD8 + T E subset survival is thought to switch to other factors, perhaps including the BIRC family member survivin/Birc5 [30] (Fig.S1D ). Work with a Bcl-2 reporter mouse, however, indicates that even at the peak of a pathogen-specific immune response, CD8 + T E populations are characterized by a spread of Bcl-2 expression levels that permits the distinction of CD8 + T E subsets with differential memory potential [31] . In line with these observations, we found that II o CD8 + T E derived from aged CD8 + T M exhibited a slight yet significant elevation of Bcl-2 as compared to I o CD8 + T E or II o CD8 + T E generated from young CD8 + T M (Fig.2I) Overall, the dynamic regulation of Bcl-2 re-expression in the memory phase ( Fig.1B /C) followed a pattern similar to that of multiple other phenotypic/functional CD8 + T M properties subject to age-associated expression modulation [1] . Since the precise pace of these changes could be experimentally accelerated or delayed as a function of initial CD8 + T N precursor frequency or infection dosage [1] , we surmised that Bcl-2 expression by CD8 + T M could be controlled in a comparable fashion. Here, we constructed p14 chimeras with titered numbers of p14 T N (2x10 2 -2x10 5 ) and challenged the mice with a standard dose of LCMV (2x10 5 pfu), or generated p14 chimeras with a fixed p14 T N number (1x10 4 ) and infection with graded dosages of LCMV (2x10 3 -2x10 7 pfu).
Measuring Bcl-2 expression by p14 T M 6-7 weeks later, we found that an increase of p14 T N input numbers enhanced, while an escalation of the virus challenge dose reduced respective Bcl-2 levels in p14 T M (Fig.2J ). In summary, our results demonstrate that aging CD8 + T M become more resistant to apoptosis, that their improved survival and that of their II o progeny is principally controlled through increased Bcl-2 expression, and that the specific conditions of CD8 + T E generation determine the pace of progressive Bcl-2 upregulation by CD8 + T M .
Cytokine receptor expression, signaling & homeostatic proliferation of aging CD8 + T M
In direct relation to their longevity, regulation of CD8 + T M fates under steady-state conditions also involves homeostatic proliferation, the slow and stochastic division of "resting" CD8 + T M governed by the cytokines IL-7
and IL-15 [15, 32] . In extension of our previous report [1] , we now demonstrate that a progressive upregulation of the respective cytokine receptors (CD127 and CD122) by aging CD8 + T M also pertains to the PBMC compartment and to differential CD8 + T M specificities ( Fig.3A/B ) suggesting that their homeostatic proliferation rates may be adjusted accordingly. To determine if enhanced cytokine receptor expression indeed conveyed greater responsiveness, we assessed the extent of IL-7/IL-15-induced STAT5 phosphorylation in young and old p14 chimeras. Here, aged p14 T M not only exhibited greater reactivity, but at limiting concentrations IL-7 clearly proved to be a more effective activator of STAT5 than IL-15 ( Fig.3C ). These findings extend the notion of superior IL-7 potency in the context of initial CD8 + T M formation [33] to the long-term maintenance of CD8 + T M , and complement a recent observation about enhanced IL-15 reactivity of "late" p14 T M or T CM (>8 months after infection) as compared to "early" p14 T M /T CM (d30-45) [5] . We further note that the thymic stromal lymphopoietin receptor (TSLPR) is apparently the only CD8 + T M -expressed cytokine receptor subject to a gradual downmodulation over time [1] , a pattern that could contribute to the amplified IL-7 reactivity of aged CD8 + T M as it may permit enhanced complex formation of CD127 with CD132 rather than TSLPR [34] .
While the above findings correlate increased CD127/CD122 expression with CD8 + T M reactivity to IL-7/IL-15, we also noted a certain extent of constitutive STAT5 phosphorylation among p14 T M analyzed directly ex vivo, similar to the basal STAT5 phosphorylation observed in human CD8 + T cell subsets of undefined specificity [35] . Additional control experiments confirmed this conclusion ( Fig.S2A ) but unexpectedly, the levels of constitutive STAT5 phosphorylation remained unaltered in aging antiviral CD8 + T M populations ( Fig.3D ). Since the level of active STAT5 appears to control homeostatic proliferation rates [36] , stable pSTAT5 expression by endogenously generated CD8 + T M therefore suggested that their homeostatic proliferation rates, despite enhanced sensitivity to IL-7/IL-15, might not be accelerated. This prediction was reinforced by our longitudinal p14 T M GSEAs that demonstrated a negative (though not significant) enrichment of cell cycle-associated genes and thus also argued against an accelerated CD8 + T M turnover ( Fig.S2B ). Indeed, as assessed by ex vivo Ki67 expression, homeostatic proliferation of blood-borne LCMV-specific CD8 + T M was unaffected by age ( Fig.3E ), a contention corroborated through the comparable in vivo BrdU incorporation by young and old CD8 + T M in various lymphatic and nonlymphoid tissues (NLTs) ( Fig.3F ). Thus, in contrast to murine CD8 + T MP of undefined specificity [37] , homeostatic proliferation rates of virus-specific CD8 + T M were largely independent of age but remained susceptible to modulation by tissue-specific microenvironments as shown for young CD8 + T M [38] .
Finally, it is important to note that homeostatic proliferation rates are not simply an intrinsic property of phenotypically defined CD8 + T M subsets. For example, the CD62L hi CD8 + T CM population, previously reported to exhibit higher homeostatic proliferation rates than CD8 + T EM [17, 39] , accumulates in the spleen over time [1, 17] without causing an overall acceleration of homeostatic turnover ( Fig.3E /F). And although we confirmed the differential homeostatic proliferation rates of splenic CD8 + T CM vs. T EM in young LCMV-immune mice, we found no differences in other tissues such as LNs (Fig.3G ). The absence of a simple correlation between CD8 + T M subsets, rates of homeostatic proliferation, cytokine receptor (CD127/CD122) and even corresponding tissuespecific cytokine (Il7/Il15) expression levels ( Fig.S2C ) constitutes an important caveat that needs to inform further investigations into the homeostasis of CD8 + T M populations.
Metabolic adaptations of aging CD8 + T M.
Initial CD8 + T E differentiation and CD8 + T M generation are both controlled and accompanied by varied metabolic adaptations. Activation of "quiescent" naïve CD8 + T N engages a "metabolic switch" that endows emerging CD8 + T E with high rates of aerobic glycolysis and glutaminolysis to support an anabolic metabolism;
the subsequent development of CD8 + T cell memory is characterized by a gradual return to metabolic quiescence and a preferential reliance on fatty acid oxidation (FAO) and oxidative phosphorylation (OxPhos) to meet the changing energy demands [40] . The extent to which established CD8 + T M populations may further adapt their metabolism over time, however, remains little explored [5] . We previously reported that aging CD8 + T M exhibit a subtle yet significant increase of cellular size and "granularity/complexity" (determined by forward [FSC] and side scatter [SSC] properties, respectively) [1] , a process most likely controlled by mTOR activity [41, 42] . Indeed, we now find that basal mTOR protein (though not mRNA) expression by antiviral CD8 + T M increased with age as did message for ribosomal protein S6 (Rps6, a downstream target of the mTORC1 complex involved in the regulation of cell size, proliferation and glucose homeostasis) and, importantly, the degree of Rps6 protein phosphorylation ( Fig.4A/B ). Although the convergence of elevated mTORC1 activity, cell size and recall capacity of aged CD8 + T M [1] is consistent, these adjustments would appear to run counter to the shift towards reduced glycolysis and increased OxPhos as observed for the earlier transition from CD8 + T E to young T M stage [40] . Interestingly, however, most recent work indicates that enforcement of sustained glycolysis and suppression of OxPhos does not compromise but rather may accelerate CD8 + T M formation [43] . Therefore, to assess the extended evolution of metabolic CD8 + T M profiles, we reviewed our temporal GSEAs and found that ~25% of all pathways up-or downregulated by p14 T M over time could in fact be assigned to the broad KEGG category of "metabolism". Here, a collective depletion of carbohydrate, energy, lipid, amino acid and glycan pathways in aging p14 T M suggested a continued trend towards metabolic quiescence yet the gene sets comprising glycolysis, nucleotide and glutathione metabolism were simultaneously enriched ( Fig.4C and not shown). In the absence of significant differences for the majority of these temporally regulated pathways ( Fig.4C ), the age-associated alterations of CD8 + T M metabolism are therefore expected to be subtle but nevertheless should be reflected in a distinct modulation of glucose and fatty acid utilization.
With regard to glucose metabolism, our transcriptional p14 T M data indicated that within the family of facilitative glucose transporters, robust gene expression was restricted to stable Slc2a1/Glut1 and progressively declining Slc2a3/Glut3 mRNA species (Fig.4D ). Yet while corresponding Glut3 protein expression levels mirrored the decline of Slc2a3 mRNA, total Glut1 expression was subject to distinct translational modulations:
high in CD8 + T E , reduced in young CD8 + T M but intermediate in aged CD8 + T M (Fig.4E ). Importantly, a specific interrogation of surface Glut1 confirmed the enhanced expression by old vs. young CD8 + T M , and the differential Glut1 levels in CD8 + T E/M populations correlated precisely with their respective glucose uptake capacities ( Fig.4E ). In contrast, greater rates of glucose uptake by CD8 + T N than either CD8 + T E or young T M , also observed in other reports [44, 45] , did not correspond to enhanced Glut1 levels in our experiments ( Fig.4E) ; however, neither glucose uptake nor in vitro survival of resting T cells is affected by Glut1-deficiency and may instead rely on related transporters such as Glut3 [46] . The notion of enhanced glucose utilization by aged as compared to young CD8 + T M is further supported by the pattern of CD8 + T cell-expressed insulin receptor (Insr/CD220) that significantly increases with CD8 + T M age ( Figs.S3A & 4F) . Insulin not only regulates glucose uptake but also acts as a major growth factor that increases protein translation [47] . In fact, of the 26 gene sets demonstrating a progressive enrichment in aging p14 T M , nearly half are captured under the general category of "genetic information processing" that includes pathways for transcription; translation; folding, sorting and degradation; as well as replication and repair ( Fig.S3B ).
If CD8 + T M aging fosters a trend towards increased glucose utilization, it should simultaneously decrease OxPhos and FA utilization, and our GSEAs indicate that this is the case (Fig.4C ). To directly determine the amount of stored fat in CD8 + T cells, we quantified neutral lipid content in CD8 + T N and virus-specific CD8 + T E/M populations. As expected [45] and albeit subtle, young CD8 + T M contained fewer neutral lipids than CD8 + T E but old CD8 + T M stored even less (Fig.4G ). In further agreement with O'Sullivan et al. [45] we also noted a decreased capacity for long-chain FA (FL C 16 ) and low-density lipoprotein (LDL) uptake in young CD8 + T M as compared to CD8 + T E , a competence that, importantly, eroded even further with age ( Fig.4G ). Reduced FA uptake, however, is not per se an indicator for decreased FA metabolism since CD8 + T M fuel their bioenergetics needs in a "futile cycle" that utilizes extracellular glucose to support both increased FA synthesis (FAS) and FAO [45] . With the aim to delineate the relative contribution of FAS and FAO to CD8 + T M metabolism [48] specifically in the context of aging, we incubated the various CD8 + T cell populations in the presence of titrated amounts of Lastly, we wanted to determine how the subtle metabolic alterations in aging CD8 + T M populations relate to their overall "metabolic fitness". Here, our determination of mitochondrial mass and membrane potential failed to document consistent differences but in aggregate, we observed a trend towards enhanced fitness by old CD8 + T M ( Fig.S3F and not shown). In support of this assessment, we also note that PGC-1α, a master regulator of mitochondrial biogenesis most recently shown to improve the bioenergetics of LCMV-specific CD8 + T cells in a chronic infection model [44] , is comparatively elevated at both mRNA and protein levels in aged CD8 + T M ( Fig.S3G/H ). In summary, we conclude that the "mixed metabolic phenotype" of long-term CD8 + T M populations emerges through a partial reversal of metabolic adaptations that control and accompany the original transition from CD8 + T E to young CD8 + T M stage, and that the "intermediate" metabolic profile of old CD8 + T M likely contributes to their greater recall capacity [1, 5] . Defining a precise inflection point for this "metabolic switch"
during CD8 + T M aging will be difficult given the delicate and only partial nature of metabolic adaptations, but it is well possible that a net effect of these processes may become discernible only at later stages of the extended CD8 + T M evolution [5] .
Increasing abundance and precipitous maturation of aging CD8 + T M in the splenic white pulp.
The extended maturation of circulating aging CD8 + T M populations [1] proceeds in the face of their continued anatomic redistribution but without apparent alteration of total CD8 + T M maintained in various lymphoid organs and NLTs [14, [49] [50] [51] . Although there are some exceptions to this rule, e.g. the natural decline of influenza virus-specific CD8 + T M in lung airways and associated loss of immune protection [52] , it has remained unclear how exactly the phenotypic conversion of aging CD8 + T M may modulate their trafficking patterns [53] .
The gradual re-expression of CD62L in particular [1, 17] would be expected to affect the anatomical distribution of older CD8 + T M . For example, young p14 T EM and T CM subsets, distinguished according to CD62L expression and with differential sensitivity to the chemokines CCL19 and CXCL12, preferentially localize to splenic red pulp (RP) and white pulp (WP), respectively [54] . The progressive upregulation of CD62L, CCR7 (CCL19 receptor) and CXCR4 (CXCL12 receptor) by aging splenic CD8 + T M [1] , confirmed and extended here to blood-borne CD8 + T M with different LCMV specificities ( Fig.5A and not shown), may therefore also promote an altered positioning of these cells within the spleen. To evaluate this possibility, we employed the i.v. injection of fluorochrome-conjugated CD8β antibody that readily labels CD8 + T cells found in vascular contiguous compartments (including RP) but not tissue stroma and parenchyma (including WP) [55, 56] (Fig.S4A ). While the total number of specific CD8 + T M in the spleen does not change over time [14] , their differentiation according to RP/WP residence demonstrated a pronounced increase from ~15% to ~60% in the WP of aging mice changes recently reported for the aging murine spleen [57] .
Progressive accumulation of aging CD8 + T M in peripheral lymph nodes.
Another potential consequence of increasing CD62L, CCR7 and/or CXCR4 expression by aging CD8 + T M ( Fig.5A ) is the gradual acquisition of an enhanced LN tropism [58, 59] , especially since earlier trafficking studies have demonstrated the unequivocal requirement for virus-specific CD8 + T M -expressed CD62L [60] and chemokine receptors [50] to enter LNs under steady-state conditions. Indeed, a first suggestion in support of this conjecture has come from a recent study that reported a greater proportion of "late" p14 T M as compared to "early" p14 T M in inguinal LNs [5] . To examine if the "LN-homing phenotype" of aged CD8 + T M confers a preferential redistribution to peripheral LNs at large, we enumerated specific CD8 + T M in young and old LCMVimmune mice. In the absence of age-associated changes in LN cellularity, we observed an up to 10-fold increase of specific CD8 + T M frequencies and numbers in aged mice ( Fig.6A-C) , and a longitudinal analysis of mesenteric LNs (MLN) revealed a slow and continuous accumulation of CD8 + T M with an estimated population doubling time of ~190 days ( Fig.6D ). We next assessed the capacity of aging CD8 + T M to enter peripheral LNs by performing a competitive homing experiment ( Fig.6E ). In brief, p14 T M were enriched from young and old LCMV-immune p14 chimeras, differentially labeled with CFSE, combined at a ratio of 1:1, and transferred into naïve B6 recipients. Upon retrieval 48h later, this ratio was skewed to >10:1 in favor of old p14 T M in peripheral LNs but not blood or spleen demonstrating that aging CD8 + T M in fact acquire a capacity for facilitated LN access ( Fig.6E ).
Increased CD62L expression promotes improved LN access for aging CD8 + T M .
Similar to polyclonal CD8 + T M ( Thus, the LN tropism of CD8 + T M , in addition to their survival/Bcl-2 expression ( Fig.2J ), multiple phenotypic and functional properties, and their II o reactivity [1] , can be experimentally controlled in a fashion that accelerates or delays the CD8 + T M maturation process at large.
Loss of aging CD8 + T M from peripheral blood and nonlymphoid tissues.
Based on the above evidence, and in the absence of locally increased homeostatic proliferation most likely emerged through the redistribution of CD8 + T M from other anatomic reservoirs. We estimated, according to the numbers of specific CD8 + T M in the LNs of young and aged LCMV-immune mice ( Fig.6A -C) as well as the number and variable size of murine LNs [61] , that over a period of ~17 months, up to 1x10 6 To test this prediction, we first evaluated the preservation of D b NP 396 CD8 + T M in the blood by combining data obtained in numerous experiments performed over a period of several years. Interestingly, the aggregate data uncovered an unexpected biphasic loss of blood-borne CD8 + T M (Fig.7C ). In the period of ~7-14 weeks after virus challenge, and thus well after completion of the "contraction phase" in the spleen [14] , specific CD8 + T M numbers continued to decline in the blood before attaining seemingly stable levels around day 100 after infection. A careful inspection of subsequent time points, however, revealed a subtle decrease of blood-borne CD8 + T M with a theoretical population half life of ~3 years (Fig.7C ). This finding is noteworthy since it evokes, even under experimental conditions that optimize CD8 + T M preservation, the natural decline of blood-borne virusspecific CD8 + T M in humans [12] . In as much as the cumulative ~60% loss (between weeks 7 and 86) of specific CD8 + T M from peripheral blood also reflects a changing CD8 + T M abundance in the larger BMP, these cells could provide a relevant contribution to the growing CD8 + T M LN pool. The biphasic erosion of blood-borne CD8 + T M ( Fig.7C ), however, would seem at odds with the dynamics of CD8 + T M accumulation in the LNs (Fig.6D ). We therefore proceeded with an enumeration of young and old CD8 + T M in NLTs (peritoneal cavity, liver, lung, kidney) and observed a 1.4-to 2.7-fold relative reduction of aged CD8 + T M numbers (Fig.7D ). Thus, both theoretical considerations and experimental results support the notion that a loss of aging CD8 + T M is not restricted to the lung [5, 52] but involves the BMP and especially NLTs in general.
CD8 + T M trafficking and the "tissue resident memory T cell (T RM )" paradigm.
How can the above conclusions be reconciled with the notion that NLTs are preferentially populated by non-recirculating T RM [62] ? According to Steinert et al., ~9% of CD8 + T M found in NLTs can in fact recirculate, a fraction that is lower in some (e.g., lung) but higher in other (e.g., liver) compartments [56] . These calculations are based on parabiosis experiments that were conducted, similar to multiple other studies, over a period of just ~1 month [56] . A notably longer observation period was employed by Jiang et al. who found that the frequencies of skin CD8 + T RM in the donor parabiont declined by ~2-fold between 8 and 24 weeks after surgery suggesting limits to CD8 + T RM longevity and/or mobilization of the CD8 + T RM compartment [63] . The latter observation is not only in agreement with a classic study that reported a trend towards continued equilibration of CD8 + T RM within intestinal lamina propria and epithelium for at least 8 weeks [50] but also consistent with our experiments that compare CD8 + T M populations recovered from NLTs at time points separated by ~18 months and thus may offer sufficient time for some CD8 + T RM to re-enter the circulation. Of further importance is the recent observation that traditional flow cytometry-based methods of CD8 + T M quantification in NLTs markedly underestimate the true number of CD8 + T M found in these tissues [56] . While our quantification of young and old CD8 + T M in liver, lung and kidney therefore cannot accurately account for absolute CD8 + T M numbers, it is the relative reduction of CD8 + T M recovered from the NLTs of aged LCMV-immune animals, readily revealed even by use of flow cytometry, that is important for the present context. Consistent with this interpretation, we also observed an ageassociated decrease of CD8 + T M numbers in the peritoneal cavity ( Fig.7D) , an organ that is not subject to the inefficiency of CD8 + T M recovery from solid NLTs. Finally, in considering the role of CD8 + T RM as highly effective first responders to infections re-encountered at body surfaces [64] and the established role of LN-residing CD8 + T M as direct precursors for II o CD8 + T E expansions, it is worth noting that LN CD8 + T M themselves also act as "gate-keepers" and immediate effectors capable of curtailing peripheral infections and preventing systemic viral spread [65] . In fact, following a footpad LCMV challenge of mice that received limiting numbers of young vs.
old CD8 + T M , we found that only the latter population prevented systemic dissemination of the virus (not shown).
Therefore, the gradual accumulation of aging CD8 + T M in peripheral LNs, even at the expense of CD8 + T M in NLTs, may represent a progressively enhanced "strategic positioning" in anatomic locations that constitute a critical site for both local pathogen control and the coordination of effective recall expansions [66] .
Increased accumulation of old CD8 + T M in primary lymphatic tissues.
Considering though in contrast to LNs, accumulation of aging CD8 + T M in the BM was independent of CD62L ( Fig.S5C ). In competitive homing experiments similar to those shown in Fig.6E but conducted here with endogenously generated CD8 + T M , aged CD8 + T M also displayed a slightly enhanced BM tropism; at the same time, their facilitated LN access was expectedly more pronounced ( Fig.7E ).
Finally, the apparently generalized pattern of age-associated increasing CD8 + T M abundance in both secondary (splenic WP, LN) and primary (BM) lymphatic tissues also warranted an analysis of the thymus.
Interestingly, we observed an almost 2-fold relative increase of old over young CD8 + T M populations for this primary lymphatic organ (counts normalized to 10 6 cells); due to thymic involution, however, absolute numbers of aged CD8 + T M were expectedly reduced, here by a factor of ~2.5 (Fig.7F ).
CONCLUSIONS
As detailed in our recent work on CD8 + T cell memory [1] , aging of established antiviral CD8 + T M populations introduces a series of cumulative molecular, phenotypic and functional changes that collectively confer naïve-like T cell traits, greater proliferative potential and protective capacities onto old CD8 + T M populations. To account for these sweeping processes in a simple fashion, we have introduced the "rebound model" of CD8 + T M maturation according to which the extent of initial CD8 + T E differentiation directly determines the kinetics of protracted CD8 + T M "de-differentiation" [1] . We now demonstrate that this remodeling process also expression [1-3, 5, 17] . We further document that the gradual acquisition of mature phenotypes by aging CD8 + T M populations proceeds through co-regulated modulation of receptor/ligand expression and at a pace that is contingent on the specific microenvironment (i.e., accelerated in splenic WP, delayed in RP). In addition, all of these dynamics are readily captured by the basic tenet of the "rebound model" that posits a broad harmonization of CD8 + T M and T N traits while simultaneously reinforcing the development of a simple CD8 + T M core signature [1] .
The imperviousness of aging CD8 + T M to changes of their basal homeostatic proliferation rates, however, was unexpected. Our results document a simple association between cytokine receptor (CD122/CD127) expression levels and functionality, and the importance of CD127 abundance as well as the intermittent rather than continuous IL-7 signaling for the homeostasis of naïve CD8 + T cell populations has been illustrated by the work of A. Singer's group [69] . Yet we previously noted a lack of association between CD127/CD122 expression levels on CD8 + T M and their tissue-specific pace of homeostatic turnover [38] , and the heightened responsiveness of aged CD8 + T M to IL-7 and IL-15 as shown here failed to confer increased homeostatic proliferation rates. Old CD8 + T M may therefore have adopted an exquisite balance with age-associated changes in various tissue microenvironments; the homeostasis of CD8 + T N and pathogen-specific CD8 + T M , though reliant on the same cytokines (IL-7, IL-15), may be regulated in a differential manner; or other factors contributing to the regulation of CD8 + T M homeostasis may become more dominant over time. We also note that changing levels of CD8 + T M -expressed CXCR4, recently proposed to control the homeostatic turnover of CD8 + T M [67] , had no apparent impact on their homeostatic self-renewal over time. A recent analysis of human CD45RO + CD8 + T MP populations also found no differences in homeostatic turnover rates between young and healthy elderly individuals [70] .
Though subtle, the metabolic adaptations of aging CD8 + T M would appear to contradict the "rebound model" since they are characterized by a partial re-acquisition of CD8 + T E -like profiles, in particular an increase of glucose utilization [40] . Yet the shift towards enhanced glucose uptake, decreased neutral lipid content as well as reduced FA and LDL uptake also indicates a gradual return, albeit incomplete, towards respective CD8 + T N capacities. Nevertheless, CD8 + T N consistently displayed greater sensitivity to in vitro FAS and FAO inhibition than either young or old CD8 + T M suggesting that the latter cells' distinctive and evolving metabolic profiles should be considered part of the memory "core signature" that distinguishes CD8 + T M from T N .
Three aspects of CD8 + T M homeostasis will require further clarification to define relevant age-associated adaptations and their potential impact on II o reactivity and immune protection in more detail. 1., the progressive conversion of aging CD8 + T M documented primarily for spleen and blood [1] [2] [3] 5] will have to be considered for other tissues [62] , In summary, the present work confirms and expands the central tenets of the "rebound model" [1] by documenting the fundamentally temporal nature of CD8 + T M homeostasis and identifying associated determinants for improved CD8 + T M survival, metabolic alterations and lymphoid tissue homing that collectively brace aged CD8 + T M for enhanced II o expansion and immune protection. The dynamic adaptations of long-term CD8 + T cell memory and the possibility to accelerate or delay these processes at large [1] provides an experimental framework for the focused interrogation of suitable targets that may be exploited for the prophylactic or therapeutic modulation of specific CD8 + T M responses. To this end, we have explored elsewhere the specific contribution of 16 molecular pathways to the improved II o reactivity of aged CD8 + T M populations (manuscripts in preparation).
METHODS
Ethics statement
All procedures involving laboratory animals were conducted in accordance with recommendations in the . According to these criteria, up to ~30% of aging mice were excluded from the study.
Tissue processing, cell purification and adoptive transfers (AT)
Lymphocytes were obtained from blood, spleen, lymph nodes (LNs), thymus, peritoneal cavity and bone marrow (BM) according to standard procedures; for an estimate of total BM cells, the content from one femur was multiplied with a coefficient of 15.8 [38] (Fig.7D ). For isolation of lymphocytes from solid NLTs (liver, lung, kidney), terminally anesthetized mice were sacrificed by total body perfusion with PBS and subsequent organ processing and gradient centrifugation as described [38] . Enrichment of splenic T cells was performed with magnetic beads using variations and adaptations of established protocols. 1., for construction of p14 chimeras recipients, and challenge with LCMV ( Fig.2H ).
Flow cytometry
All reagents and materials used for analytical flow cytometry are summarized in Table S1 , and our basic staining protocols are described and/or referenced in ref. [1] ; in some cases, expression levels were normalized by dividing the GMFI of experimental by the GMFI of isotype control stains (Fig.2I ). Additional methodologies 1A, 2E, 4C, S2B & S3B) . We treated time series as continuous phenotypes and used Pearson's correlation to determine ranks for each gene. Enrichment scores (ES) were obtained as the maximum deviation from zero of P hit -P miss , where P hit and P miss are fractions of genes in or not in specific gene sets weighted by their correlations up to a given position in the rank; p values were estimated from random permutation tests by comparing random ES versus observed ES [82] . For qRT-PCR ( Fig.S2C) , RNA isolation and DNAseI digestion was performed with spleen, LN and BM cells stored in RNA later using RNAqueous-4PCR kit per manufacturer protocol (Ambion/Life Technologies). RNA integrity was evaluated on a RNA Nano chip run on a Bioanalyzer 2100 (Agilent Technologies); RNA integrity numbers (RIN) for all samples were 8.2-9.6. The cDNA first strand transcription was performed using 370ng of total RNA with the iScript cDNA synthesis kit following manufacturer protocol (BioRad). 6E & S5B) . Homing assays using endogenously generated CD8 + T M populations were conducted in an analogous fashion using 5-6x10 4 D b NP 396 + CD8 + T M each, B6.CD45.1 recipients and retrieval of donor cells from various tissues 20h later (Fig.7E) . In some cases, mixed donor populations were incubated for 1h in complete RPMI (1.5x10 7 cells/ml) in the presence or absence of 25ng/ml pertussis toxin (RnD Systems) prior to washes and transfer (Fig.S5B ). For trafficking studies under conditions of CD62L blockade (Fig.7A & S5C) , B6 mice were treated with a single i.p. injection of 200µg αCD62L (MEL-14) or rIgGa control (RTK2758) 2h before transfer of ~5x10 5 aged p14 T M and retrieval 48h later.
Microarray analyses and qRT-PCR
Further details about all antibodies are provided in Table S1 .
Statistical analyses
Data handling, analysis and graphic representation was performed using Prism 6.0c (GraphPad Software).
All data summarized in bar and line diagrams are expressed as mean ± 1 standard error (SEM), and asterisks 
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S1 BCL2  TNFRSF10B  BIRC2  IKBKB  NFKBIA  TNFSF10  ENDOG  PRKAR2A  PIK3CB  AKT3  PRKAR1A  IL3RA  AIFM1  IRAK1  IKBKG  TRAF2  ATM  CHUK  XIAP/BIRC4  FAS  PIK3CA  IL1RAP  AKT2  CASP6  MAP3K14  PIK3R1  IRAK2  BAX  PPP3R1  PRKACA  BAD  PIK3R5  PPP3CA  CASP8  BIRC3  PRKACB  FADD  EXOG  NFKB1  RELA  IRAK4  DFFA  PIK3CD  PRKAR2B  CAPN2  CAPN1  RIPK1  TRADD  PPP3CB  TNF  BCL2L1  DFFB  CFLAR  AKT1  PIK3R3  CASP9  MYD88  BID  CASP7  ENDOD1  APAF1  PIK3CG  PRKX  TNFRSF1A  CASP3  IRAK3 low high ANAPC5  TFDP1  MYC  E2F1  CHEK2  CDC7  MAD2L1  E2F4  CDC14B  DBF4  MCM5  MCM7  CREBBP  CDK4  CDC16  PTTG1  HDAC2  SMC1A  CHEK1  CDKN2C  CCND1  YWHAZ  SMAD2  BUB1B  MCM4  ATR  GSK3B  GADD45A  TFDP2  ATM  STAG1  CDK6  CDC27  MCM2  YWHAE  RBL1  ANAPC11  STAG2 EP300  CCND3  CCNE1  ANAPC10  YWHAQ  MAD2L2  CDC25A  CDC20  MCM3  CDC26  YWHAH  CCNA2  CDC14A  FZR1  YWHAG  GADD45B  PCNA  YWHAB  CCNE2  SKP2  CDKN1B  ANAPC13  RBX1  CDK7  SMAD4  PRKDC  MCM6  ZBTB17  E2F3  CDC23  TGFB1  CDK2  BUB3  MDM2  ANAPC1  WEE1  RAD21  HDAC1  SMAD3  RB1  ANAPC2  CUL1  E2F5  SMC3  GADD45G  ABL1  ANAPC7  E2F2  RBL2 was quantified 24h later as detailed in Methods; given the differential survival of the different CD8 + T cell populations in the absence of inhibitor, their relative survival under this condition was set for comparative purposes at 100%. All data are displayed as inhibitor titration curves (left) and under select conditions of inhibitor concentration (right). C., fatty acid synthase (FASN) inhibitor C75. D., adipose triglyceride lipase (ATGL) inhibitor atglistatin. E., inhibition of lysosomal acidifaction by chloroquine (n=4 mice/group; representative data from one of two experiments). F., JC-1 stains of young and aged D b NP 396 + CD8 + T M . JC-1 is a membrane-permeant dye that exhibits potential-dependent accumulation in mitochondria as indicated by a green (~529nm) to red (~590) fluorescence shift; accordingly, mitochondrial depolarization decreases the red/green fluorescence intensity (incubation with FCCP prior to JC-1 stains was used as a control to dissipate the electrochemical proton gradient). G., temporal regulation of Ppargc1a expression (p14 T E/M microarray data). H., PGC-1α (Ppargc1a gene product) expression by young and old LCMV-specific CD8 + T M (n=4 mice/group). were transferred into B6 recipients treated with rIgG2a isotype or αCD62L antibody, and retrieved 48h later as detailed in Fig.7A . Note the enhanced accumulation of aged p14 T M in spleen and BM under conditions of CD62L blockade, likely constituting a compensatory increase due to p14 T M exclusion from LNs (n=4 mice/group). 
